AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05510427
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT05510427
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT04980027
Drug: Insulin glargine (U300)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
Trial: NCT02142868
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
Trial: NCT02142868
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
Trial: NCT04555785
Drug: Wilate
RxNorm normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
Trial: NCT06107868
Drug: RP-6306
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
Trial: NCT06107868
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is an antineoplastic agent.
Trial: NCT06107868
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is an antineoplastic agent.
Trial: NCT05263674
Drug: Rapid sedation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
Trial: NCT02699138
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg of trazodone to be administered orally once.
Trial: NCT04940338
Drug: Dexamethasone Ophthalmic
RxNorm normalized name: dexAMETHasone ophthalmic
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
Trial: NCT00002214
Drug: Capravirine
RxNorm normalized name: Capravirine
DrugBank: Capravirine (DB08502)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00956176
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
Trial: NCT05852704
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Trial: NCT05132127
Drug: sutimlimab
RxNorm normalized name: Sutimlimab
DrugBank: Sutimlimab (DB14996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
Trial: NCT04662060
Drug: Acebilustat
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule administered orally once daily
Trial: NCT05630989
Drug: combination therapy with MEKi-HCQ
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This cohort will receive combination therapy with MEKi-HCQ.
Trial: NCT05630989
Drug: combination therapy with MEKi-EGFRi
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This cohort will receive combination therapy with MEKi-EGFRi.
Trial: NCT04812002
Drug: PD-1 inhibitor， bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both drugs are given intravenously
Trial: NCT05298059
Drug: CPP-ACPF
RxNorm normalized name: CPPD
DrugBank: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (DB14196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
Trial: NCT04969068
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
Trial: NCT06007222
Drug: Aspirin group
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
Trial: NCT06249997
Drug: Leniolisib
RxNorm normalized name: Leniolisib
DrugBank: Leniolisib (DB16217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
Trial: NCT05193721
Drug: SHR-1901
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
Trial: NCT04786470
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine infusion via transversus abdominis plane catheter.
Trial: NCT04786470
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline infusion via transversus abdominis plane catheter.
Trial: NCT06122181
Drug: HS-10384 tablets
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing of HS-10384 orally in a fasting state
Trial: NCT06224127
Drug: Active c tactile fiber stimulation
RxNorm normalized name: fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hair brushes that activate c tactile fibers
Trial: NCT00002354
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002354
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05585307
Drug: GS-1720
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05585307
Drug: Standard of Care (Substudy 02)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC
Trial: NCT05585307
Drug: GS-6212
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05686863
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remazolam for sedation in children undergoing bidirectional endoscopy
Trial: NCT05686863
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine
Trial: NCT05686863
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol
Trial: NCT03612466
Drug: 153Sm-DOTMP
RxNorm normalized name: 153sm-dotmp
DrugBank: DOTMP SM-153 (DB18484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
Trial: NCT03612466
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
Trial: NCT04864821
Drug: Targeting CD276 CAR T cells
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeting CD276 autologous chimeric antigen receptor T cells
Trial: NCT03612466
Drug: Mozobil
RxNorm normalized name: Mozobil
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
Trial: NCT04799743
Drug: Resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
Trial: NCT05376761
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
Trial: NCT04854759
Drug: Amantadine Hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, capsule
Trial: NCT05275465
Drug: HH-006
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different dose levels of HH-006
Trial: NCT05381454
Drug: Mitoquinone/mitoquinol mesylate
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoquinone/mitoquinol mesylate
Trial: NCT05073679
Drug: Naltrexone Hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg x 3 days then 50mg a day thereafter
Trial: NCT04632459
Drug: pembrolizumab plus ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles.
Trial: NCT06364787
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Trial: NCT04683796
Drug: 100% Autologous platelet rich plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Trial: NCT04706897
Drug: Dexmedetomidine, ketamine and lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
Trial: NCT04487808
Drug: Pecan
RxNorm normalized name: PECAN
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
Trial: NCT04931368
Drug: Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: De-escalated induction treatment with R/HD-MTX and two courses of MATRix
Trial: NCT00338546
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05050214
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
Trial: NCT00338546
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06341686
Drug: Letermovir 480 MG
RxNorm normalized name: letermovir 480 MG
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
Trial: NCT06341686
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
Trial: NCT05133323
Drug: Lu AG09222
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG09222 will be administered per schedule specified in the arm.
Trial: NCT05484414
Drug: SRP-3D (diethylamide)
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Trial: NCT05162443
Drug: adagrasib (MRTX849)
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Trial: NCT00337090
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06225973
Drug: TL-925
RxNorm normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL-925 is an eye drop.
Trial: NCT05621447
Drug: TAS-303, [14C]TAS-303
DrugBank: TAS-303 (DB18808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration on day 1
Trial: NCT00215891
Drug: PEG-Interferon a-2b + Ribavirin
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04868773
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral cabozantinib
Trial: NCT04868773
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TAS-102 (trifluridine and tipiracil)
Trial: NCT05716724
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
Trial: NCT05862428
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
Trial: NCT04957368
Drug: Nitrous Oxide 99 %
RxNorm normalized name: nitrous oxide 99 %
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
Trial: NCT04957368
Drug: Oxygen + Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
Trial: NCT06029530
Drug: Atropine Ophthalmic
RxNorm normalized name: atropine ophthalmic
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops to be administered once daily
Trial: NCT00002305
Drug: Flucytosine
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002305
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002305
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06418113
Drug: Chemotherapy Stupp Protocol
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
Trial: NCT05266040
Drug: Valacyclovir 500 MG
RxNorm normalized name: valacyclovir 500 MG
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Trial: NCT05654454
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg
Trial: NCT05654454
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2